在对宫颈癌辅助治疗的研究中，基因治疗代表着一种合理的新方法，选择合适的靶点是宫颈癌基因治疗的关键。TPX2是一个受细胞周期严格调控并在细胞有丝分裂纺锤体形成过程中发挥重要作用的微管相关蛋白。它的高表达与许多肿瘤的形成及染色体不稳定密切相关。它在恶性肿瘤中的高表达，会导致细胞中心体异常扩增、异倍体形成及细胞恶性转化，进而促进细胞增殖，影响周期和凋亡，并与肿瘤分化、转移和复发明显相关。阻断其表达可抑制止肿瘤细胞生长，有望成为肿瘤治疗的候选靶点。 本项目基于本人前期研究TPX2基因在宫颈癌的表达与其恶性生物学行为密切相关的基础上，进一步用慢病毒为载体，对TPX2基因进行过表达及沉默，分别来研究TPX2基因对人宫颈癌hela细胞的增殖、浸润、周期、凋亡的影响及机制，为以TPX2为靶点的宫颈癌的基因治疗提供实验依据。

In the study of adjuvant therapy for the cervical cancer, the gene therapy is representing a reasonable new method,and choosing the appropriate target point is the key to the gene therapy .TPX2 protein is a kind of microtubμle-associated protein that is tightly regμlated by the cell cycle and play an important role in mitotic spindle formation process. Its expression related to the formation and chromosomal instability of many tumor.The researchers found that TPX2 is highly expressed in some malignant tumors and resμlt to abnormal centrosome amplification，aneuploidy and cell malignant transformation，which is contribut to cell proliferation,apoptosis,and have a relationship with differentiation, metastasis,recurrence of tumor.Blocking its expression can inhibit the growth of tumor cells.TPX2 is expected to be a new candidate targets of tumor therapy.This studies is based on my preliminary study that the expression of TPX2 gene in cervical cancer is closely related to its malignant biological behaviors.Using lentiviral as the carrier,overexpressing and silencing the TPX2 gene,the effect and mechanism of TPX2 gene on the proliferation, invasion, cycle, apoptosis of the human cervical cancer hela cells were studied, which will provide experimental evidence for taking TPX2 as the target in the gene therapy for cervical cancer.